News

In rare cases, Lambert-Eaton myasthenic syndrome (LEMS) may be associated with cancer of the esophagus, the tube that carries food down to the stomach, as highlighted in a recent case study. “This case emphasises the importance of diagnosing LEMS before tumour detection, maintaining suspicion for LEMS in atypical presentations,…

The U.S. Food and Drug Administration (FDA) has tentatively approved Lupin’s generic version of Firdapse (amifampridine) for people with Lambert-Eaton myasthenic syndrome (LEMS), ages 6 and older, according to a company press release. This means the treatment satisfies all the requirements to be marketed in the U.S.

Note: This story has been updated March 6, 2025, to correct a quote from Mindy Henderson, MDA vice president of disability outreach and empowerment. The Muscular Dystrophy Association (MDA) is once again hosting its annual gathering, the MDA Clinical & Scientific Conference. The 2025 event will take place…

Firdapse (amifampridine), an approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS), is now available to people in Japan with the rare autoimmune disease. The therapy, available in the form of 10 mg tablets, was launched by Dydo Pharma. Dydo is responsible for the development and commercialization…

An agreement between Catalyst Pharmaceuticals and Teva Pharmaceuticals has ended a U.S. patent litigation case that began when Teva applied to produce and market a generic version of Firdapse (amifampridine) for the treatment of Lambert-Eaton myasthenic syndrome (LEMS). Under the terms of the settlement, announced…

Anti-CD19 CAR T-cell therapy was found to be effective in treating a 54-year-old man with Lambert-Eaton myasthenic syndrome (LEMS) who wasn’t responding to other immune-suppressing and symptomatic treatments, according to a case report from researchers in Germany. The team’s observations suggest that this type of cell therapy may be…

The National Organization for Rare Disorders (NORD) is offering a financial support program to aid people with Lambert-Eaton myasthenic syndrome (LEMS) and their caregivers. The LEMS Patient Assistance Program can provide financial support to cover out-of-pocket healthcare costs linked directly to treatment and care for the autoimmune disease, according…

Firdapse (amifampridine) has been approved in Japan to treat people with Lambert-Eaton myasthenic syndrome (LEMS). The therapy will be supplied in the form of oral tablets containing 10 mg of amifampridine, according to Catalyst Pharmaceuticals, the company that holds Firdapse’s licensing rights in North America. In collaboration with…

Firdapse (amifampridine) can help ease symptoms of Lambert-Eaton myasthenic syndrome (LEMS) in patients who don’t have an underlying cancer and its efficacy is consistent regardless of how long a delay there is before it’s started. That’s according to a study, “Safety, efficacy and steroid-sparing…

Lambert‐Eaton myasthenic syndrome (LEMS) may, in rare cases, manifest with severe respiratory muscle weakness leading to respiratory failure, researchers noted in a case study. “Establishing the association of LEMS with respiratory disease could lead to timely identification of LEMS, diagnosis of an underlying malignancy (if unknown), and initiation of…